Patents by Inventor Loren A. Ornelas
Loren A. Ornelas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970714Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: GrantFiled: July 2, 2020Date of Patent: April 30, 2024Assignee: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Publication number: 20230340420Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: January 9, 2023Publication date: October 26, 2023Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Patent number: 11572545Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: GrantFiled: June 16, 2017Date of Patent: February 7, 2023Assignee: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Publication number: 20200370023Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: July 2, 2020Publication date: November 26, 2020Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Publication number: 20200332316Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.Type: ApplicationFiled: June 30, 2020Publication date: October 22, 2020Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Xiaojiang Cui, Dhruv Sareen, Loren A. Ornelas
-
Patent number: 10745671Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: GrantFiled: January 14, 2019Date of Patent: August 18, 2020Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Patent number: 10738323Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.Type: GrantFiled: July 11, 2014Date of Patent: August 11, 2020Assignee: Cedars-Sinai Medical CenterInventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas
-
Publication number: 20190194624Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: June 16, 2017Publication date: June 27, 2019Applicant: Cedars-Sinai Medical CenterInventors: Dhruv SAREEN, Loren A. ORNELAS, Clive SVENDSEN
-
Publication number: 20190136203Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: January 14, 2019Publication date: May 9, 2019Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Patent number: 10221395Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: GrantFiled: June 16, 2016Date of Patent: March 5, 2019Assignee: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Publication number: 20170362574Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: June 16, 2016Publication date: December 21, 2017Applicant: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Publication number: 20170107498Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from lymphoblastoid B-cells and lymphoblastoid B-cell lines. Such methods and compositions find use in regenerative medicine applications.Type: ApplicationFiled: June 5, 2015Publication date: April 20, 2017Applicant: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren Ornelas, Robert Barrett
-
Publication number: 20160145642Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.Type: ApplicationFiled: July 11, 2014Publication date: May 26, 2016Applicant: Cedars-Sinai Medical CenterInventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas